Approximately 1.3 percent of the world population say that chronic nasal congestion (rhinitis) negatively impact their lives to the point that they need to seek help. Those affected often have difficulty breathing which results in further problems, such as a dry mouth, snoring and impaired speech ability. The symptoms are often perceived as common but chronic colds.
When rhinitis patients are referred to a specialist, they are usually treated by primary care units and at ear-nose-throat clinics (ENT). The treatment options that exist today mainly consist of decongesting nasal sprays as well as fairly advanced surgical procedures. None of the alternatives are without risk and the prolonged use of nasal spray can become addictive. A sensible preventive alternative is simply lacking from the healthcare market. K.O.S. treatment has been shown in studies to be a valuable alternative that has few or no unexpected side effects.
Our treatment for nasal congestion is CE marked and has been approved for sale in the Nordics, the EU, and Saudi Arabia, where we sell through our distributors. In these markets, some 2.5 million people are prospective Chordate patients. Based on only one treatment per year and with the treatment method having proved effective for 55 percent of treated patients, this corresponds to a maximum potential turnover of around SEK 850 million per year for treatments with the current pricing.
In 2020, a study was published by the University of Amsterdam that analyzed the data material from an older study from 2013-14. It concluded that the K.O.S. treatment has a significantly better effect than placebos. This confirms our view that the market for K.O.S. has great potential.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.